The Hindu·6 min read·medium
Why Semaglutide is an inflection point for India’s generics sector?
S
Santosh V. Perumal
✦AI Summary
India's pharmaceutical industry is facing a critical juncture as it attempts to capitalize on the patent expiry of the diabetes and weight-loss drug Semaglutide. Over 40 Indian firms are planning to launch generic versions to compete in both domestic and international markets.
More than a supply chain issue and missing the first mover status, Semaglutide episode has rather exposed systemic chinks and could prove costly for India’s pharmaceutical industry, which supplies about 20% of the world’s generic medicines by volume.
businesshealtheconomy
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in